Booth #514, D&A exhibit
Revolutionizing healthcare: The potential of AI-Rad Companion for precision lung cancer screening and beyond
About this session
Lung cancer remains the world’s most common cause of cancer death with 1.8 million deaths in the year 2020 worldwide. As lung cancer is mainly detected in a late-stage setting, there is an urgent need for early detection and hence, improved survival rates. Through a clear risk profile, a population subgroup prone to frequent occurrences of lung cancer can be identified, benefitting from a screening program. However, the necessary low-dose CT examinations for this demand additional resources in an increasingly strained healthcare system. Therefore, it is imperative to employ AI methods to simplify the detection of pulmonary nodules and enable direct volumetric evaluation. Yet, we must not lose sight of other medical conditions associated with the same risk factors. It is crucial to exclude or confirm coronary artery disease (CAD) in the acquired CT scans. Additionally, an assessment of osteoporosis risk should be undertaken, recognizing the holistic potential of AI in healthcare diagnostics. Learn more in this session from PD Dr. med. Isabelle Ayx.
Isabelle Ayx
University Hospital Heidelberg, Germany
Kathrin Hörner
Global Clinical Marketing Manager Digital & Automation
Image courtesy of Klinikum Nürnberg, Nuremberg, Germany
AI-Rad Companion consists of several products that are (medical) devices in their own right, and products under development. AI-Rad Companion is not commercially available in all countries. Future availability cannot be ensured.
The statements by Siemens Healthineers’ customers described herein are based on results that were achieved in the customer's unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.